This trial is enrolling by invitation!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Dementia, Parkinsonism, Mild Cognitive Impairment or REM Sleep Behavior Disorder
and you are
between 40 and 90
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.

Provided treatments

  • Drug: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
  • Device: Single photon emission computed tomography (SPECT) scan

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01453127. The sponsor of the trial is Mayo Clinic and it is looking for 500 volunteers for the current phase.
Official trial title:
DaTSCAN Imaging in Aging and Neurodegenerative Disease